ASPIRIN DESENSITIZATION AND IT’S CLINICAL ACKNOWLEDGEMENT IN PATENTS WITH CORONARY ARTERY DISEASE

Abstract

Acetylsalicylic acid (ASA) is recommended in patients with coronary artery disease, and is an important part of the dual antiplatelet therapy after coronary stent implantation. Notably, around 2% of patients do not receive aspirin therapy due to hypersensitivity (which is manifested as urticaria, angioedema, asthma or anaphylactic reaction). In such cases, aspirin desensitization can be attempted to counter the hypersensitivity. The idea is to “deceive” the immune system by administering small doses of ASA over a long period of time, thus preventing an allergic reaction. There are many desensitization protocols based on the time they require to be completed, which ranges from hours do days, and the procedure is with a high successful rate. We present a clinical case of a 55-years old male with unstable angina and known ASA allergy who was able to receive dual antiplatelet therapy after stent implantation thanks to the desensitization procedure we performed.